... 16, 17), the rate of MACE ranged from 3.1%,to 12.8%, at the end of the two-year period. In our trial, however, the incidence of MACE in the ZES treated group was 10% at the end of the two ... initial and final angiograms. The glycoprotein IIb/IIIa inhibitor (Tirofiban) was administered at the operator’s discretion. All patients maintained an-ti-platelet therapy following the procedure ... ongoing ENDEAVOR clinical trials program. Th e results of these initial trials indicate that the ZES is safe and reduces the rates of clinical and angiographic restenosis in patients with...